<DOC>
	<DOCNO>NCT00493441</DOCNO>
	<brief_summary>The study design find optimum AVN944 dose use combination gemcitabine patient pancreatic cancer see combination 2 drug effective treat pancreatic cancer use gemcitabine alone .</brief_summary>
	<brief_title>AVN944 Combination With Gemcitabine Treatment Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients histologically cytologically confirm adenocarcinoma pancreas eligible curative intent resection without adjuvant radiation therapy Measurable disease define RECIST criterion No prior chemotherapy pancreatic cancer include prior `` radiosensitizing '' chemotherapy Patients candidate receive gemcitabine first line treatment adenocarcinoma pancreas Age &gt; 18 year Karnofsky Performance Score less equal 60 Patients must recover clinically significant effect prior surgery prior radiotherapy Adequate bone marrow , hepatic renal function evidence : Serum total bilirubin &lt; 2.0 mg/dL AST/ALT ( SGOT/SGPT ) &lt; 4X ULN reference lab ; Serum creatinine &lt; 2.0 mg/dL ; ANC &gt; 1.5 x 109/L ; Platelet count &gt; 100 x 109/L , Hgb &gt; 9.0 g/dL Female patient childbearing potential well fertile men partner agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) Patients legal representative must able read , understand provide write informed consent participate trial . Patients life expectancy &lt; 3 month Patients know CNS metastases Patients uncontrolled active infection Prior treatment IMPDHinhibitor Patients known hypersensitivity component AVN944 gemcitabine History prior malignancy within past 5 year except curatively treat nonmelanoma skin cancer ; cervical intraepithelial neoplasia , localized prostate cancer current PSA &lt; 1.0 mg/dL Patients receive concurrent investigational therapy receive investigational therapy within 14 day first schedule day dose ( investigational therapy define treatment currently regulatory authority approve indication ) . Clinically significant toxicity therapy must resolve &lt; Grade 2 . Patients pregnant lactate Myocardial Infarction within past 6 month Patients clinically significant intraventricular conduction delay Any intercurrent medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . History solid organ transplant Known HIV Hepatitis B C ( active , previously treat ) Previous treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>